[Form 4] Rocket Pharmaceuticals, Inc. Insider Trading Activity
Martin L. Wilson, General Counsel and officer of Rocket Pharmaceuticals, reported sales of common stock tied to vested restricted stock units. On 08/18/2025 he sold 1,004 shares at $3.065 and on 08/19/2025 he sold 588 shares at $2.996 to satisfy tax withholding for RSU vesting. After these transactions he beneficially owned 135,462 shares. The filing notes RSUs convert one-for-one into common stock and that the sales were made specifically to cover tax obligations related to vesting.
Martin L. Wilson, consulente legale e dirigente di Rocket Pharmaceuticals, ha venduto azioni ordinarie legate a unit脿 azionarie vincolate (RSU) maturate. Il 18/08/2025 ha ceduto 1.004 azioni a 3,065$ e il 19/08/2025 ha ceduto 588 azioni a 2,996$ per coprire le ritenute fiscali dovute al vesting delle RSU. Dopo queste operazioni deteneva beneficiariamente 135.462 azioni. Nel documento si precisa che le RSU si convertono in azioni ordinarie in rapporto uno a uno e che le vendite sono state effettuate esclusivamente per adempiere agli obblighi fiscali connessi al vesting.
Martin L. Wilson, abogado general y directivo de Rocket Pharmaceuticals, declar贸 ventas de acciones ordinarias vinculadas a unidades restringidas de acciones (RSU) que hab铆an vencido. El 18/08/2025 vendi贸 1.004 acciones a 3,065$ y el 19/08/2025 vendi贸 588 acciones a 2,996$ para cubrir la retenci贸n fiscal por la consolidaci贸n de las RSU. Tras estas transacciones pose铆a beneficiariamente 135.462 acciones. La declaraci贸n indica que las RSU se convierten en acciones ordinarias a raz贸n de una por una y que las ventas se realizaron espec铆ficamente para satisfacer obligaciones fiscales relacionadas con el vesting.
Martin L. Wilson, Rocket Pharmaceuticals鞚� 氩曤瓿犽 瓴� 鞛勳洂鞚� 旮绊檿鞝�(vested) 鞝滍暅欤检嫕雼渼(RSU)鞕� 甏�霠悳 氤错喌欤茧ゼ 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 2025雲� 8鞗� 18鞚检棎 1,004欤茧ゼ 欤茧嫻 3.065雼煬鞐�, 2025雲� 8鞗� 19鞚检棎 588欤茧ゼ 欤茧嫻 2.996雼煬鞐� 毵る弰頃橃棳 RSU 頇曥爼鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頄堨姷雼堧嫟. 鞚� 瓯半灅霌� 鞚错泟 攴鸽姅 鞁れ鞝侅溂搿� 135,462欤�毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 RSU臧� 1雽�1 牍勳湪搿� 氤错喌欤茧 鞝勴櫂霅橂┌ 鞚措矆 毵る弰電� 頇曥爼瓿� 甏�霠悳 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 鞚措（鞏挫雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Martin L. Wilson, conseiller juridique et dirigeant de Rocket Pharmaceuticals, a d茅clar茅 des ventes d'actions ordinaires li茅es 脿 des unit茅s d'actions restreintes (RSU) acquises. Le 18/08/2025, il a vendu 1 004 actions 脿 3,065$ et le 19/08/2025, 588 actions 脿 2,996$ afin de couvrir les retenues fiscales li茅es 脿 la vesting des RSU. Apr猫s ces op茅rations, il d茅tenait b茅n茅ficiairement 135 462 actions. Le dossier pr茅cise que les RSU se convertissent en actions ordinaires 脿 raison d'une pour une et que ces ventes ont 茅t茅 r茅alis茅es sp茅cifiquement pour satisfaire les obligations fiscales li茅es 脿 la acquisition.
Martin L. Wilson, General Counsel und leitender Angestellter von Rocket Pharmaceuticals, meldete Verk盲ufe von Stammaktien, die mit ausge眉bten Restricted Stock Units (RSU) verkn眉pft waren. Am 18.08.2025 verkaufte er 1.004 Aktien zu 3,065$ und am 19.08.2025 weitere 588 Aktien zu 2,996$, um die Steuerabz眉ge im Zusammenhang mit dem Vesting der RSU zu begleichen. Nach diesen Transaktionen hielt er wirtschaftlich 135.462 Aktien. In der Einreichung wird angegeben, dass RSU im Verh盲ltnis eins zu eins in Stammaktien umgewandelt werden und die Verk盲ufe ausdr眉cklich zur Deckung steuerlicher Verpflichtungen aus dem Vesting erfolgten.
- None.
- None.
Insights
Insider sold shares to satisfy RSU tax withholding; ongoing ownership remains in place.
The reported sales are routine and tied to compensation mechanics rather than open-market disposals for diversification. The filing discloses that RSUs convert one-for-one and that shares were sold solely to cover tax withholding obligations, which aligns with common practice for executives. Remaining beneficial ownership of 135,462 shares retains potential alignment with shareholder interests, though the filing does not state total outstanding percentage, limiting assessment of influence.
Small, non-discretionary insider sales; limited informational value for valuation.
The transactions total 1,592 shares across two days at ~ $3.03 average, a modest volume that appears administrative. Because proceeds were used for tax withholding on vested RSUs, this does not indicate a change in confidence. The form lacks broader context on total insider holdings as a percentage of outstanding shares, so market impact is likely negligible.
Martin L. Wilson, consulente legale e dirigente di Rocket Pharmaceuticals, ha venduto azioni ordinarie legate a unit脿 azionarie vincolate (RSU) maturate. Il 18/08/2025 ha ceduto 1.004 azioni a 3,065$ e il 19/08/2025 ha ceduto 588 azioni a 2,996$ per coprire le ritenute fiscali dovute al vesting delle RSU. Dopo queste operazioni deteneva beneficiariamente 135.462 azioni. Nel documento si precisa che le RSU si convertono in azioni ordinarie in rapporto uno a uno e che le vendite sono state effettuate esclusivamente per adempiere agli obblighi fiscali connessi al vesting.
Martin L. Wilson, abogado general y directivo de Rocket Pharmaceuticals, declar贸 ventas de acciones ordinarias vinculadas a unidades restringidas de acciones (RSU) que hab铆an vencido. El 18/08/2025 vendi贸 1.004 acciones a 3,065$ y el 19/08/2025 vendi贸 588 acciones a 2,996$ para cubrir la retenci贸n fiscal por la consolidaci贸n de las RSU. Tras estas transacciones pose铆a beneficiariamente 135.462 acciones. La declaraci贸n indica que las RSU se convierten en acciones ordinarias a raz贸n de una por una y que las ventas se realizaron espec铆ficamente para satisfacer obligaciones fiscales relacionadas con el vesting.
Martin L. Wilson, Rocket Pharmaceuticals鞚� 氩曤瓿犽 瓴� 鞛勳洂鞚� 旮绊檿鞝�(vested) 鞝滍暅欤检嫕雼渼(RSU)鞕� 甏�霠悳 氤错喌欤茧ゼ 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 2025雲� 8鞗� 18鞚检棎 1,004欤茧ゼ 欤茧嫻 3.065雼煬鞐�, 2025雲� 8鞗� 19鞚检棎 588欤茧ゼ 欤茧嫻 2.996雼煬鞐� 毵る弰頃橃棳 RSU 頇曥爼鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頄堨姷雼堧嫟. 鞚� 瓯半灅霌� 鞚错泟 攴鸽姅 鞁れ鞝侅溂搿� 135,462欤�毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 RSU臧� 1雽�1 牍勳湪搿� 氤错喌欤茧 鞝勴櫂霅橂┌ 鞚措矆 毵る弰電� 頇曥爼瓿� 甏�霠悳 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 鞚措（鞏挫雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Martin L. Wilson, conseiller juridique et dirigeant de Rocket Pharmaceuticals, a d茅clar茅 des ventes d'actions ordinaires li茅es 脿 des unit茅s d'actions restreintes (RSU) acquises. Le 18/08/2025, il a vendu 1 004 actions 脿 3,065$ et le 19/08/2025, 588 actions 脿 2,996$ afin de couvrir les retenues fiscales li茅es 脿 la vesting des RSU. Apr猫s ces op茅rations, il d茅tenait b茅n茅ficiairement 135 462 actions. Le dossier pr茅cise que les RSU se convertissent en actions ordinaires 脿 raison d'une pour une et que ces ventes ont 茅t茅 r茅alis茅es sp茅cifiquement pour satisfaire les obligations fiscales li茅es 脿 la acquisition.
Martin L. Wilson, General Counsel und leitender Angestellter von Rocket Pharmaceuticals, meldete Verk盲ufe von Stammaktien, die mit ausge眉bten Restricted Stock Units (RSU) verkn眉pft waren. Am 18.08.2025 verkaufte er 1.004 Aktien zu 3,065$ und am 19.08.2025 weitere 588 Aktien zu 2,996$, um die Steuerabz眉ge im Zusammenhang mit dem Vesting der RSU zu begleichen. Nach diesen Transaktionen hielt er wirtschaftlich 135.462 Aktien. In der Einreichung wird angegeben, dass RSU im Verh盲ltnis eins zu eins in Stammaktien umgewandelt werden und die Verk盲ufe ausdr眉cklich zur Deckung steuerlicher Verpflichtungen aus dem Vesting erfolgten.
FAQ
What transactions did Martin L. Wilson report on Form 4 for RCKT?
Why were the shares sold according to the filing?
How many shares does the reporting person own after the transactions?
What is the reporting person鈥檚 role at Rocket Pharmaceuticals (RCKT)?
Do the holdings include restricted stock units (RSUs)?
